Share on StockTwits

Shares of Cepheid (NASDAQ:CPHD) have earned a consensus rating of “Hold” from the nineteen ratings firms that are covering the company, American Banking and Market News reports. Nine equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $48.32.

Shares of Cepheid (NASDAQ:CPHD) traded down 0.42% on Tuesday, hitting $37.73. 26,083 shares of the company’s stock traded hands. Cepheid has a 1-year low of $34.60 and a 1-year high of $55.89. The stock’s 50-day moving average is $42.54 and its 200-day moving average is $46.77. The company’s market cap is $2.649 billion.

Cepheid (NASDAQ:CPHD) last announced its earnings results on Thursday, July 17th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.16. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $115.47 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. Analysts expect that Cepheid will post $-0.52 EPS for the current fiscal year.

A number of research firms have recently commented on CPHD. Analysts at S&P Equity Research raised their price target on shares of Cepheid from $6.58 to $8.30 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Separately, analysts at ISI Group upgraded shares of Cepheid from a “sell” rating to a “neutral” rating in a research note on Monday, August 11th. They now have a $38.50 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Cepheid in a research note on Friday, August 8th. They now have a $41.00 price target on the stock.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.